Autologous Hematopoietic Cell Transplantation HSCT) for Treatment- Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation (ASBMT) (2019)

The ASBMT Task Force recommends revising the recommended indication for AHCT in MS to “standard of care, clinical evidence available”, for patients with relapsing forms of MS (RRMS or progressive MS with superimposed activity) who have prognostic factors that indicate a high risk of future dis-ability, including ongoing clinical relapse or MRI lesion activity despite treatment with available DMTs, especially if disease activity continues despite treatment with high-efficacy DMTs and/or worsening disability. This position paper does not provide recommendations on preferred methods for mobilization and stem cell collection, graft manipulation (eg, CD34+ selection), cell dose, condition-ing regimen, or post-transplantation supportive care.

Read the full article in American Society for Blood and Marrow Transplantation